BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Oxford Gene Technology Ltd. to Showcase New RNA-Seq Service in Live Webinar


10/25/2012 11:16:50 AM

Oxford, UK – 25 October 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a live webinar on Thursday 15th November (3pm BST). Dr Daniel Swan, Senior NGS Computational Biologist at OGT, will discuss how RNA-Seq is revolutionising the field of transcriptomics by delivering unprecedented biological insight into the way cells function. He will also explain how this can only be reliably achieved through good experimental design — ensuring the data generated represents the true biology — and rigorous data analysis procedures.

The 45-minute webinar will be essential viewing for everyone interested in learning why RNA-Seq delivers novel biological discoveries and how best to design an NGS gene expression study that delivers true biological insight. As part of the webinar, Dr Swan will utilise OGT’s NGS data reporting interface, which makes it quick, easy and intuitive to visualise gene and transcript expression levels, identify isoforms and perform SNP and indel analysis for a range of eukaryotes. To register for the webinar please visit the sign-up page.

For more information about OGT’s RNA-Seq, targeted sequencing and other genetic analysis services, go to www.ogt.co.uk.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.co.uk

W: www.ogt.co.uk ; Twitter: @OxfordGeneTech

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Diagnostic Biomarkers: Utilising proprietary next generation technologies, OGT is building a rich patent-protected portfolio of promising biomarkers for early-stage cancer and autoimmune disease detection. The biomarker pipeline includes advanced programmes in colorectal cancer, prostate cancer and pancreatic cancer plus the autoimmune disease systemic lupus erythematosus (SLE). OGT is currently assessing partnership opportunities to commercialise these biomarker panels.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->